The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Oct 31, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness of a double dose of Furmonertinib, a medication designed to treat non-small cell lung cancer (NSCLC) in patients who have developed resistance to another drug called Osimertinib. The study focuses on individuals with advanced NSCLC who have specific mutations in their cancer cells (known as EGFR mutations) and have shown slow progression of their disease after using Osimertinib. Participants must be at least 18 years old and have not previously received Furmonertinib or any other new cancer treatments recently.

If you or a loved one might be eligible for this trial, you should be aware that it is not yet recruiting participants. Those who join will be monitored closely to assess how well the double-dose treatment works. Additionally, participants will need to have measurable tumors that haven't been treated with radiation before and must have undergone a biopsy where no new treatment targets were found. This trial aims to find new options for patients facing challenges with their current cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old;
• • 2. EGFRm NSCLC of local progression (IIIB stage) or metastasis (IV stage);
• • 3. previously confirmed to have EGFR (Ex19del or L858R) mutation, or T790M, received Osimertinib treatment. According to Recist 1.1 imaging findings, the focus progressed slowly and there was no systemic explosive progress (definition of slow progress: disease control \> 6 months, slightly increased tumor load and symptom score ≤ 1);
• • 4. patients who intend to use Furmonertinib (double dose, 160mg) anticancer therapy;
• • 5. At least one tumor lesion in the patient can meet the following requirements: it has not been irradiated in the past and can be accurately measured, the longest diameter of the baseline phase is ≥ 10mm (in the case of lymph nodes, short axis ≥ 15mm is required), and the measurement method can be chest CT or PET-CT, as long as repeated measurements can be completed accurately;
• • 6. No treatable target was found in the second biopsy after drug resistance;
• • 7. The survival time was more than 3 months;
• Exclusion Criteria:
• • 1. Patients who have been treated with Furmonertinib;
• • 2. Patients who intend to use anticancer therapy other than Furmonertinib recently;
• • 3. Contraindications for the use of Furmonertinib;